back to
back to

Program: Tuesday (26.10.2010)

08:30 – 10:00

Room: Großer Saal

Scientific Session Transplantation

  • Christian Gisselbrecht
  • Norbert Schmitz

  • Randomized Trials

    • Norbert Schmitz

  • Role of allo-TX

    • Anna Sureda

  • Double APBSCT

    • Franck Morschhauser

  • Long Term Outcome of High-Dose Salvage Therapy for Patients with Early Stage Hodgkin Lymphoma (HL) Who Failed Initial Treatment with Combined Modality Treatment or Chemotherapy Alone

    • Andreas Rimner

  • Relapse of Hodgkin Lymphoma after Autologous Stem Cell Transplantation (ASCT): Identi cation of Prognostic Factors Predicting Outcome

    • Carmen Martinez

  • Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma: a Retrospective Analysis of Data from the German Stem cell Transplantation Registry (DRST)

    • Christoph Scheid

10:30 – 12:00

Room: Großer Saal

Scientific Session New drugs

  • Peter Johnson
  • Anas Younes

  • SGN-35

    • Robert Chen

  • LBH-589

    • Anas Younes

  • Everolimus for Relapsed/Refractory HL

    • Patrick Johnston

  • Lenalidomide

    • Nancy Bartlett

  • Extended Follow-Up of the Safety of 131I Radiolabelled Anti-CD25 Antibody, Basiliximab, in Patients with CD25-Positive, Refractory Hodgkin Lymphoma

    • Neha Bhatnagar

  • Initial Results from the SAPHIRE Study: a Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients

    • Jan Walewski

12:00 – 13:15

Room: Großer Saal

Satellite Symposium New Mobilisation Strategies in Autologous Stem Cell Transplantation

  • Norbert Schmitz

  • The Role and Challenges of Autologous Transplantation in Hodgkin Lymphoma

    • Karl Peggs

  • Optimizing Stem Cell Mobilization with Plerixafor in Hodgkin Lymphoma

    • Peter Dreger

13:15 – 14:00

Room: Kleiner Saal

Main Program Posterwalk

14:00 – 15:30

Room: Großer Saal

Scientific Session PET

  • Markus Dietlein
  • Aaron Polliack

  • PET for Lymphoma Staging

    • Bruce Cheson

  • Interim PET

    • Andrea Gallamini

  • PET during Follow-Up

    • Martin Hutchings

  • Contribution of PET/CT in the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients entered in the H10 Trial

    • Theodore Girinsky

  • Early Interim FDG-PET during Intensi ed BEACOPP Therapy for Advanced-Stage Hodgkin Lymphoma Shows a Lower Positive Predictive Value than during ABVD

    • Francesca Fiore

  • A Bone Marrow Biopsy is Not Necessary in the Staging of Hodgkin Lymphoma (HL) Patients in the FDG-PET Era

    • Simon Richardson

16:00 – 17:30

Room: Großer Saal

Scientific Session Advanced Stage

  • George Canellos
  • Patrice Carde

  • Update on Stanford V

    • Ranjana Advani

  • Debate: Kairos or Chronos? Early versus Late Intensi cation in Advanced HL

    • Patrice Carde
    • Volker Diehl
    • Richard Fisher

  • HD15-PET: Final Analysis

    • Andreas Engert

  • Intensi ed ABVD for Newly Diagnosed Patients with Advanced-Stage Classical Hodgkin Lymphoma

    • Filippo Russo

  • BEACOPP is Superior to ABVD in Patients with Advanced Hodgkin Lymphoma and High Tumor Burden

    • Paolo Gobbi

17:30 – 19:00

Room: Großer Saal

Main Program Closing Remarks

  • Andreas Engert

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.